Litcius/Paper detail

2-year outcomes of ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW extension study): prospective follow-up of an open label, randomised controlled trial

Neil Marlow, Andreas Stahl, Domenico Lepore, Alistair R. Fielder, James D. Reynolds, Qi Zhu, Annemarie Weisberger, Daniel P. Stiehl, Brian W. Fleck

2021The Lancet Child & Adolescent Health92 citationsDOI

Topics & Concepts

Retinopathy of prematurityMedicineRanibizumabRandomized controlled trialProspective cohort studyPediatricsOpen labelLow birth weightLaser therapySurgeryGestational agePregnancyBevacizumabLaserChemotherapyPhysicsOpticsGeneticsBiologyRetinopathy of Prematurity StudiesNeonatal Respiratory Health ResearchInfant Nutrition and Health
2-year outcomes of ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW extension study): prospective follow-up of an open label, randomised controlled trial | Litcius